ArticlePloS one2012
A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- High Expression of Aurora Kinase A (AURKA) is Associated with Aggressive Tumor Biology and Therapeutic Response in ER+/HER2- Breast Cancer.Annals of surgical oncology · 2026Article
- Dual cutoffs of estrogen receptor positivity define prognostic and predictive subgroups in breast cancer.iScience · 2026Article
- Article
- Hypoxia induced responses are reflected in the stromal proteome of breast cancer.Nature communications · 2023Article
- Article
- Article
- High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.Breast cancer research and treatment · 2022Article
- Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.Cancers · 2021Article
- PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients.BMC bioinformatics · 2020Article
- Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy.Endocrine-related cancer · 2018Article
- Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.Oncotarget · 2016Article
- Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma.BMC bioinformatics · 2016Article
- Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy.Assay and drug development technologies · 2015Article
- Use of ChemoFx® for Identification of Effective Treatments in Epithelial Ovarian Cancer.PLoS currents · 2015Article
- Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.Urologic oncology · 2014Review
- Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.Nature reviews. Urology · 2014Review
- Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.International journal of medical sciences · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have reported conflicting assessments of the ability of cell line-derived multi-gene predictors (MGPs) to forecast patient clinical outcomes in cancer patients, thereby warranting an investigation into their suitability for this task. Here, 42 breast cancer cell lines were evaluated by chemoresponse tests after treatment with either TFAC or FEC, two widely used standard combination chemotherapies for breast cancer. We used two different training cell line sets and two independent prediction methods, superPC and COXEN, to develop cell line-based MGPs, which were then validated in five patient cohorts treated with these chemotherapies. This evaluation yielded high prediction performances by these MGPs, regardless of the training set, chemotherapy, or prediction method. The MGPs were also able to predict patient clinical outcomes for the subgroup of estrogen receptor (ER)-negative patients, which has proven difficult in the past. These results demonstrated a potential of using an in vitro-based chemoresponse data as a model system in creating MGPs for stratifying patients' therapeutic responses. Clinical utility and applications of these MGPs will need to be carefully examined with relevant clinical outcome measurements and constraints in practical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.